The patient advocacy groups that partner with the Rare Diseases Clinical Research Network are working hard to support rare disease patients and families during the COVID-19 pandemic. Collected here are several resources they have developed to support their patient and family communities. This post will be updated as new resources are added.
A strong collaboration between researchers and patient advocacy groups in the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is demonstrating how partnering with patients can accelerate discoveries for rare diseases.
Interested in learning more about the Rare Diseases Clinical Research Network (RDCRN)’s fourth funding cycle and hearing stories of patient engagement in research? Plan to visit the RDCRN’s poster and exhibit table at Rare Disease Day at NIH on Friday, February 28 in Bethesda, Maryland. If you’re not able to attend in person, follow the action on social media using the hashtags #RDDNIH and #RDCRNPatientPartners.
With a focus on the patient and hope for a cure, the National Institutes of Health’s Rare Diseases Clinical Research Network (RDCRN) is launching a new logo. The mark at the center of the logo highlights what is at the core of the network’s research—a rising, hopeful and cured patient:
Even though it was almost seven years ago, I remember my final job interview at Cincinnati Children’s as though it happened yesterday. I’m guessing that not many people can say they walked directly from their son’s hospital room into a job interview, but that was me on day seven of what would turn out to be a 10-day hospital stay for our four-year-old son.
The National Institutes of Health (NIH) has awarded approximately $31 million in grants in fiscal year 2019 to 20 teams – including five new groups – of scientists, clinicians, patients, families and patient advocates to study a wide range of rare diseases through the RDCRN. An additional $7 million has been awarded to a separate data coordinating center to support these research efforts. These research teams, called Consortia, will work to better understand rare diseases and move potential treatments closer to the clinic.
Dr. Rothenberg, the Principal Investigator for CEGIR, has been awarded the highest honor bestowed by the International Eosinophil Society for his major contributions to the advancement of our understanding of the eosinophil.